

1-1-2020

## Flavonoid intake and its association with atrial fibrillation

Nicola P. Bondonno  
*Edith Cowan University*

Kevin Murray

Catherine P. Bondonno  
*Edith Cowan University*

Joshua R. Lewis  
*Edith Cowan University*

Kevin D. Croft

*See next page for additional authors*

Follow this and additional works at: <https://ro.ecu.edu.au/ecuworkspost2013>



Part of the [Medicine and Health Sciences Commons](#)

---

[10.1016/j.clnu.2020.04.025](https://doi.org/10.1016/j.clnu.2020.04.025)

Bondonno, N. P., Murray, K., Bondonno, C. P., Lewis, J. R., Croft, K. D., Kyrø, C., ... & Piccini, J. P. (2020). Flavonoid intake and its association with atrial fibrillation. *Clinical Nutrition*, 30(12), 3821-3828. <https://doi.org/10.1016/j.clnu.2020.04.025>

This Journal Article is posted at Research Online.  
<https://ro.ecu.edu.au/ecuworkspost2013/8385>

---

## Authors

Nicola P. Bondonno, Kevin Murray, Catherine P. Bondonno, Joshua R. Lewis, Kevin D. Croft, Cecilie Kyro, Gunnar Gislason, Anne Tjønneland, Augustin Scalbert, Aedin Cassidy, Jonathan P. Piccini, Kim Overad, Johnathan M. Hodgson, and Frederik Dalgaard

© 2020. This manuscript version is made available under the CC-BY-NC-ND

4.0 license <http://creativecommons.org/licenses/by-nc-nd/4.0/>

## **Flavonoid intake and its association with atrial fibrillation**

Nicola P Bondonno PhD<sup>1,2,3</sup>, Kevin Murray PhD<sup>4</sup>, Catherine P Bondonno PhD<sup>1,2</sup>, Joshua R Lewis PhD<sup>1,2</sup>, Kevin D Croft PhD<sup>2</sup>, Cecilie Kyrø PhD<sup>5</sup>, Gunnar Gislason MD PhD<sup>6,7,8</sup>, Anne Tjønneland MD, PhD, DMSc<sup>5,9</sup>, Augustin Scalbert PhD<sup>10</sup>, Aedin Cassidy PhD<sup>3</sup>, Jonathan P Piccini MD MHS<sup>11</sup>, Kim Overvad MD PhD<sup>12,13</sup>, Jonathan M Hodgson PhD<sup>1,2</sup>, Frederik Dalgaard MD<sup>6</sup>.

<sup>1</sup> School of Medical and Health Sciences, Edith Cowan University, Perth, Australia;

<sup>2</sup> School of Biomedical Sciences, The University of Western Australia, Royal Perth Hospital, Perth, Western Australia, Australia;

<sup>3</sup> Institute for Global Food Security, Queen's University Belfast, Northern Ireland;

<sup>4</sup> School of Population and Global Health, University of Western Australia, Australia;

<sup>5</sup> The Danish Cancer Society Research Centre, Copenhagen, Denmark;

<sup>6</sup> Department of Cardiology, Herlev & Gentofte University Hospital, Copenhagen, Denmark;

<sup>7</sup> The National Institute of Public Health, University of Southern Denmark, Odense, Denmark;

<sup>8</sup> The Danish Heart Foundation, Copenhagen, Denmark;

<sup>9</sup> Department of Public Health, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark;

<sup>10</sup> International Agency for Research on Cancer, Lyon, France;

<sup>11</sup> Duke Center for Atrial Fibrillation, Duke University Medical Center, Duke Clinical Research Institute, Durham, North Carolina, USA;

<sup>12</sup> Department of Public Health, Aarhus University, Aarhus, Denmark;

<sup>13</sup> Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark.

**Correspondance:** Nicola P. Bondonno

School of Biomedical Sciences, Level 4, Medical Research Foundation

Rear 50 Murray St, Perth Western Australia, Australia WA 6000

Tel: +618 92240342

Email: [n.bondonno@ecu.edu.au](mailto:n.bondonno@ecu.edu.au)

Word count: 3640 words

## ABSTRACT

2 Background & Aims: Primary prevention of atrial fibrillation (AF) through  
3 behavioural and dietary modification is a critically important and unmet need.  
4 Flavonoids are bioactive dietary compounds with promising cardiovascular health  
5 benefits. Our aim was to investigate the association between flavonoid intake and  
6 clinically apparent AF.

7 Methods: Baseline data from 55 613 participants of the Danish Diet, Cancer and  
8 Health Study, without AF, recruited between 1993 and 1997, were cross-linked with  
9 Danish nationwide registries. Total flavonoid and flavonoid subclass intakes were  
10 calculated from validated food frequency questionnaires using the Phenol-Explorer  
11 database. Associations between flavonoid intake and incident AF (first-time  
12 hospitalization or outpatient visit) were examined using restricted cubic splines based  
13 on Cox proportional hazards models.

14 Results: During a median [IQR] follow-up of 21 [18 – 22] years, 7291 participants  
15 were diagnosed with AF. Total flavonoid intake was not statistically significantly  
16 associated with risk of incident AF in the whole cohort. However, compared to the  
17 lowest quintile, a total flavonoid intake of 1000 mg/day was associated with a lower  
18 risk of AF in smokers [0.86 (0.77, 0.96)] but not in non-smokers [0.96 (0.88, 1.06)],  
19 and a lower risk of AF in high alcohol consumers [ $>20$  g/d: 0.84 (0.75, 0.95)] but not  
20 in low-to-moderate alcohol consumers [ $<20$  g/d: 0.97 (0.89, 1.07)].

21 Conclusion: Intake of flavonoids was not significantly associated with a lower risk of  
22 incident AF. However, higher intakes of flavonoids may be beneficial for those at a  
23 higher risk of developing AF.

- 24    Keywords: atrial fibrillation, flavonoids, prospective cohort study, primary
- 25    prevention, nutrition, cardiovascular disease.
- 26    Abstract word count: 240 words

## INTRODUCTION

Atrial fibrillation (AF), the most common arrhythmia, is a growing public health problem with a higher risk of thromboembolic events, cognitive impairment, heart failure, and mortality <sup>1</sup>. With an increasing prevalence <sup>2</sup>, the need for additional research of prevention methods is crucial. Development of AF relies on the progression of atrial structural remodelling that ultimately leads to anisotropic conduction and fibrillation. There is increasing evidence that inflammatory pathways contribute to both electrical and structural atrial remodelling as well as thrombogenesis <sup>3</sup>. The key role that inflammation plays in the pathophysiology of AF highlights this pathway as a potential preventive therapeutic target <sup>3</sup>.

Flavonoids, bioactive compounds found in many fruits and vegetables as well as tea, red wine and chocolate, have antiatherogenic and antithrombotic effects, attributed in part to their capacity to attenuate inflammation <sup>4</sup>. Preclinical studies provide evidence that certain flavonoids have antiarrhythmic properties, which may inhibit atrial fibrillatory activity <sup>5</sup>. In the Danish Diet, Cancer, and Health Study, higher levels of chocolate intake were associated with a lower rate of clinically apparent AF <sup>6</sup>, possibly due to the flavonoid content of chocolate <sup>7</sup>.

To our knowledge, the relationship between flavonoid intake and incident AF has not been investigated in a large cohort setting. Therefore, the primary aim of this study was to investigate the association between flavonoid intake and clinically apparent AF incidence in a large cohort of Danish men and women. Secondary aims were to investigate whether these associations differed by known risk factors for AF such as presence of hypertension, diabetes mellitus, prevalent ischemic heart disease (IHD), smoking, BMI, and alcohol intake.



## MATERIALS AND METHODS:

### Study Population

Between December 1993 and May 1997, 56 468 men and women without cancer between the ages of 50-65 years, who were residing in Copenhagen or Aarhus, were recruited into the Danish Diet, Cancer, and Health study. Details of this cohort, which forms part of the European Prospective Investigation into Nutrition and Cancer, are published elsewhere <sup>8</sup>.

All Danish citizens are assigned a unique personal identification number, which is used in all national registries. This allowed participants in the Danish Diet, Cancer, and Health study to be linked to the following registries on an individual level: (1) The Civil Registration System <sup>9</sup> containing data on age, sex, emigration, and vital status; (2) The Integrated Database for Labor Market Research Database <sup>10</sup> containing information on annual income since 1980; and (3) The Danish National Patient Register <sup>11</sup> containing information on date of hospital admissions and outpatient visits since 1978, with one primary diagnosis and one or more secondary diagnoses defined by the International Classification of Diseases (ICD); the 8<sup>th</sup> revision (ICD-8) until 1993 and the 10<sup>th</sup> revision (ICD-10) from 1994 <sup>11</sup>.

In the present study, participants were excluded if they had a prior diagnosis of AF or atrial flutter (n=437; ICD-8: 42793-42794, ICD-10: I48), if information regarding covariates was missing or if covariate values were extreme (n=214) or energy intakes implausible [ $<2\,092$  kJ/day ( $<500$ kcal/day) and  $>20\,920$  kJ/day ( $>5\,000$ kcal/day)] (n=204). This left 55 613 participants from the original cohort in the current analysis (Supplemental Figure 1).

This study was approved by the Danish Data Protection Agency (Ref no 2012-58-0004 I-Suite nr: 6357, VD-2018-117). Data were made available in an anonymized format to prevent the identification of specific individuals.

#### Flavonoid intake

Habitual intakes of total flavonoids and flavonoid subclasses were estimated from a validated food frequency questionnaire (FFQ). Participants were asked to complete the 192-item FFQ at baseline, indicating their usual frequency of intake of different food and beverage items over the past 12 months<sup>12</sup>. Using the Phenol-Explorer database<sup>13</sup>, an estimate of the flavonoid content of each food and beverage in the food frequency questionnaire was derived<sup>13, 14</sup>. The intakes of 219 flavonoid aglycones were estimated and grouped into nine subclasses based on their chemical structure [flavonols, flavones, flavanols (flavanol monomers and flavanol oligo+polymers), flavanones, isoflavones, anthocyanins, chalcones, dihydrochalcones and dihydroflavonols]. Total flavonoid intake was calculated by summing each of the flavonoid subclasses. Flavonoid subclasses with average intakes less than 5 mg/d were not analysed individually.

#### Atrial fibrillation

The primary outcome was a hospital admission or an outpatient visit with a primary or secondary diagnosis of AF or atrial flutter. These ICD codes have previously been validated in this cohort with a positive predictive value of 92.6%<sup>15</sup>. From here on in, the combined diagnosis of AF and/or atrial flutter is referred to as AF.

#### Baseline Covariates

Information on lifestyle factors and demographics were obtained from self-administered questionnaires completed by participants at baseline. Measurements such as BMI, blood pressure and total cholesterol were taken at the study centers at baseline. Average annual income, defined as household income after taxation and interest over 5-years, was used as a proxy for socio-economic status. Comorbidities were defined using ICD-8 and ICD-10 primary or secondary diagnosis codes any time prior to baseline. These consisted of chronic kidney disease (ICD-8: 580-584, ICD-10: N02-N08, N11-N12, N14, N18-N19, N26, N158-N160, N162-N164, N168, Q61, E102, E112, E132, E142, I120, M321B), chronic obstructive pulmonary disease (COPD) (ICD-8: 491-493, ICD-10: J42-J44), heart failure (ICD-8: 4270-4271, ICD-10: I42, I50, I110, J81), hyperthyroidism (ICD-8: 242, ICD-10: E05), and cancers (ICD-8: 140-209, ICD-10: C00-C99). For ischemic stroke and IHD a combination of ICD-codes and self-reported data of ischemic stroke and myocardial infarction, respectively, were used. The codes used were stroke: ICD-8 433-434; ICD-10 I63, and IHD: ICD-8: 410-414; ICD-10: I20-I25. For hypertension and diabetes, only self-reported data was used due to the underreporting of these ICD codes in The Danish National Patient Register <sup>16</sup>.

### Statistical Analysis

Participants were followed from the date of enrollment until development of AF, death, emigration, or end of follow-up (August, 2017). Nonlinear relationships were examined with restricted cubic splines; hazard ratios (HR) were based on Cox proportional hazards models. Individuals with intakes greater than 4 standard deviations above the mean were excluded in the spline analysis and HR with 95% confidence intervals (CI) were plotted for each unit of the exposure with the median

intake in quintile 1 as the reference. Nonlinearity was tested for using a chi-squared test to compare nested models. The exposure variables were categorized by quintiles of intake. HR and 95% CI for the median intakes in each quintile of the exposure variables were obtained from the splines. Cox proportional hazards assumptions were tested using log-log plots of the survival function versus time and assessed for parallel appearance. All deaths were censored rather than treated as a competing risk<sup>17</sup>. Five models of adjustment were used: 1) minimal-adjusted; 2) multivariable-adjusted; 3) multivariable-adjusted including covariates potentially on the causal pathway that may therefore introduce collider stratification bias; 4) multivariable-adjusted including potential dietary confounders; 5) multivariable-adjusted including potential dietary confounders that are also a source of flavonoids (**Supplemental Table 1**). Covariates were chosen *a priori* to the best of our knowledge of potential confounders of flavonoid intake and AF. We did not include total energy intake as a covariate in any model as we believe, given the underlying biology, that crude values of flavonoid intake are more relevant.

We stratified our analyses by baseline smoking status, alcohol intake, BMI, diabetes status, IHD status, and hypertension status in order to examine the impacts of flavonoids in different subgroups. When stratifying by alcohol intake and BMI, we excluded all participants with an alcohol intake of zero (n=1 283) and all participants with a BMI<18.5 (n=451), respectively, as these were not the subgroups of interest. We chose stratification cut-off points of 20 g pure alcohol per day and 30 kg/m<sup>2</sup> for BMI as the risk of mortality is highest beyond these levels<sup>18, 19</sup>. As there is the potential for residual confounding, when stratifying by alcohol intake and BMI the corresponding continuous variables, alcohol intake and BMI, respectively, were included in the model. Analyses were undertaken using STATA/IC 14.2 (StataCorp

LLC) and R statistics (R Core Team (2018))<sup>18</sup>. Statistical significance was set at  $p \leq 0.05$  (two-tailed) for all tests.

## RESULTS

This population of 55 613 Danish citizens were followed for a median [IQR] of 21 [18 -22] years. During this time, 7 291 participants had incident AF and 6286 participants were hospitalized for AF. Furthermore, 11 415 participants died without AF.

### Baseline Characteristics

The cohort had a median [IQR] age of 56 [52 - 60] years at baseline and 26 344 (47.4%) were male. Compared to participants in the lowest quintile of total flavonoid intake, those in the highest quintile were more likely to be female, have a lower BMI, be more physically active, have received a higher degree of education, receive a higher income and take hormone replacement therapy, aspirin, and other nonsteroidal anti-inflammatory drugs (**Table 1**). These participants were also less likely to be current smokers, have hypercholesterolemia, COPD, IHD, heart failure or diabetes, or have had a stroke. Participants with a higher flavonoid intake tended to consume more fish, fibre, fatty acids, fruit and vegetables, and less red or processed meat.

### Associations between total flavonoid and flavonoid subclass intakes and AF

Total flavonoid intakes beyond quintile 1 were associated with a 3-5% lower risk of incident AF, although this was not statistically significant after adjusting for potential lifestyle confounders (**Table 2 and Figure 2**). For AF hospitalizations, after adjusting

for potential lifestyle confounders and compared to participants in Q1, participants in Q3 and Q4 had a statistically significant 7% and 8% lower risk of an AF hospitalization, with HRs (95% CI) of 0.93 (0.87, 0.99) and 0.92 (0.86, 0.98), respectively (**Supplemental Table 2 and Supplemental Figure 2**). Similar patterns were seen for the associations between flavonoid subclasses and both incident AF and AF hospitalizations. HRs for alternative models of adjustment (3 and 5) are presented in **Supplemental Table 3** but do not differ substantively

### Stratified analyses

The inverse association between total flavonoid intake and incident AF was apparent in smokers but not in non-smokers (**Figure 3**). A total flavonoid intake of 1000 mg/d was associated with a significant 11% lower risk of AF in smokers [HR: 0.89 (0.80, 0.99)], whereas no association was observed in non-smokers [HR: 0.98 (0.90, 1.07)], compared to those consuming 173 mg/d. Similarly, an association was only apparent in participants who consumed >20 g/d of alcohol; a total flavonoid intake of 1000 mg/d was associated with a statistically significant 12% lower risk of incident AF [HR: 0.88 (0.79, 0.98)] whereas no association was observed in those who consumed ≤20 g/d of alcohol [HR: 0.99 (0.91, 1.08)]. There was some evidence for an association in participants with diabetes at baseline where 1000 mg/d total flavonoid intake was associated with a non-significant 24% lower risk of incident AF, [HR: 0.76 (0.51, 1.14)] (Figure 2). However, the number of participants with diabetes (n=1 162) at baseline was modest and the associated confidence interval in this subgroup was wide. No clear effect modification by baseline hypertension status, IHD status, or BMI was observed (Figure 3).

## **DISCUSSION**

190 The growing epidemic of AF exerts a significant and growing burden on public  
191 health. Accordingly, primary prevention of AF through behavioural and dietary  
192 modification is a critically important and unmet need. In this cohort of 55 613 Danish  
193 participants, a higher habitual intake of total flavonoids was not associated with a  
194 lower risk of incident AF. However, total flavonoid intake was associated with a  
195 lower risk of incident AF in smokers and in heavy alcohol consumers.

196 Increasing evidence highlights the role of inflammation and oxidative stress in the  
197 pathophysiology of AF, suggesting that these processes could be key therapeutic  
198 targets for primary prevention <sup>3, 19</sup>. Studies relating diet to AF incidence have  
199 primarily focused on fish derived n-3 polyunsaturated fatty acids (PUFAs), alcohol  
200 intake, caffeine, ascorbic acid, and, more recently, chocolate <sup>20</sup>. While heavy alcohol  
201 intake is invariably associated with a higher risk of AF, other, more beneficial, dietary  
202 components are not consistently favourable for AF prevention. Supplementation with  
203 a combination of PUFAs, vitamin C, and vitamin E has been shown to reduce the  
204 incidence of post-operative AF and attenuate oxidative stress and inflammation,  
205 attributed to their antioxidant capacity <sup>21</sup>. In a previous study of participants in the  
206 Danish Diet, Cancer and Health cohort, those with a higher level of chocolate intake  
207 had a lower rate of AF hospitalization, possibly due to the high flavanol content of  
208 cocoa <sup>6</sup>. However, in a recent meta-analysis of 5 cohort studies, the hazard ratio of AF  
209 was 0.96 (95% CI 0.90-1.03) for the highest versus lowest category of chocolate  
210 consumption <sup>22</sup>.

211 Preclinical and clinical studies on flavonoids suggest that they can ameliorate early  
212 markers of cardiovascular disease <sup>4</sup>, while observational studies demonstrate an  
213 inverse association between flavonoid intake and cardiovascular disease incidence

and mortality<sup>5,23</sup>. In the present cohort, we have shown that higher flavonoid intakes are associated with a lower risk of atherosclerotic cardiovascular disease<sup>24</sup>. A number of *in vitro* studies demonstrate that flavonoids can activate potassium channels or inhibit calcium channels<sup>4,5</sup>, in particular Ca<sub>v</sub>1.2 channels which are critical regulators of vascular tone and cardiac activity<sup>25</sup>. However, flavonoids are readily metabolised upon ingestion<sup>4</sup>, an important consideration that was not accounted for in most of these studies. While flavonoids were initially considered as antioxidants, they, and their *in vivo* metabolites, are now seen as signalling molecules, resulting in the downstream upregulation of enzymes that protect against oxidant damage<sup>26</sup>. It is more likely that the cardiovascular protective effects of flavonoids lie in their anti-inflammatory and anti-thrombogenic properties<sup>4</sup>.

Our finding that flavonoid intake was only modestly associated with AF hospitalizations, and not with overall incident AF, may be due to their beneficial effects on comorbidities, such as cardiovascular disease<sup>27</sup> and diabetes<sup>3</sup>, which increase the likelihood of hospitalization. In this study we were unable to determine whether the patients were admitted due to AF or whether AF was incidentally diagnosed. Due to the potential for selection bias, caution should be taken in interpreting results from studies using only AF hospitalizations as an outcome. Overall, this study shows that total flavonoid intake or any flavonoid subclass intake do not seem to be associated with incident AF.

Inflammation is a contributor to AF both direct and indirectly mediated by other inflammatory cardiovascular diseases<sup>3</sup>. Higher levels of oxidative stress and inflammation are associated with smoking, high alcohol intake, obesity, diabetes, IHD, and hypertension<sup>27</sup>. In the present study there was a significant association



between flavonoid intake and incident AF in participants who smoked or consumed high levels of alcohol. This finding supports the hypothesis that any risk reduction in AF afforded by flavonoids is likely through inflammatory and oxidative stress pathways, rather than antiarrhythmic properties.

Strengths of the present study include a large adult population followed for 23 years with limited loss to follow-up; all deaths and emigrations are captured in the Danish registries. However, as this is an observational study, we are not able to conclude causality. Although the data allowed us to adjust for many potential dietary and lifestyle confounders, unmeasured confounders, such as sleep apnoea (due to the lack of a specific ICD-8 code), could not be taken into consideration. Confounding by unobserved and potentially protective dietary factors cannot be discounted. However, adjusting for other major indicators of a healthy diet in this study did not substantially alter the risk estimates. Dietary intake and clinical data were only captured at baseline and may have changed over the 23 years of follow-up; it is unclear how changes in the trajectories of dietary intake and confounders may have impacted the observed associations. This limitation may have attenuated the power to detect an association. Although race and ethnicity were not considered, participants would most likely have been Caucasian; caution should be taken when extrapolating these findings to other populations.

Our findings suggest that higher flavonoid intakes are not associated with a lower risk of AF incidence. However, flavonoid-rich foods may be beneficial for those at a higher risk of developing AF. The association between flavonoid intake and lower AF incidence in smokers and in heavy alcohol consumers needs replication in other studies.

262 **Acknowledgements:**

263 None.

264 **Author contributions**

265 NB, FD, KM, CK, GG, JH, KO, contributed to the conception or design of the work.  
266 NP, FD, KM, CB, LJ, KC, CK, GG, AT, AS, JP, JH, KO, CA contributed to the  
267 acquisition, analysis, or interpretation of data for the work. NB drafted the  
268 manuscript. FD, KM, CB, LJ, KC, CK, GG, AT, AS, JP, JH, KO, CA critically  
269 revised the manuscript. All gave final approval and agree to be accountable for all  
270 aspects of work ensuring integrity and accuracy.

271 **Conflicts of interest:**

272 The authors declare no conflicts of interest.

273 **Funding sources:**

274 The Danish Diet, Cancer, and Health Study was funded by the Danish Cancer Society,  
275 Denmark. FD is funded by The Danish Heart Foundation (Grant number 17-R115-  
276 A7443-22062) and Gangstedfonden (Grant number A35136), Denmark. NPB is  
277 funded by a National Health and Medical Research Council Early Career Fellowship  
278 (Grant number APP1159914), Australia. The salary of JMH is supported by a  
279 National Health and Medical Research Council of Australia Senior Research  
280 Fellowship, Australia (Grant number APP1116937). CK is funded by the Danish  
281 Cancer Society (Knæk Cancer 2017, Grant number R174-A11507-17-S52).

282 **Disclaimer:**

283 Where authors are identified as personnel of the International Agency for Research on  
284 Cancer/World Health Organization, the authors alone are responsible for the views  
285 expressed in this article and they do not necessarily represent the decisions, policy or  
286 views of the International Agency for Research on Cancer / World Health  
287 Organization.

1. Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. *Circulation* 2013; 129:837–847.
2. Schnabel RB, Yin X, Gona P, et al. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. *Lancet* 2015; 386: 154-162.
3. Hu Y-F, Chen Y-J, Lin Y-J, et al. Inflammation and the pathogenesis of atrial fibrillation. *Nat Rev Cardiol* 2015; 12: 230.
4. Williamson G, Kay CD and Crozier A. The Bioavailability, Transport, and Bioactivity of Dietary Flavonoids: A Review from a Historical Perspective. *Compr Rev Food Sci Food Saf* 2018; 17: 1054-1112.
5. Scholz EP, Zitron E, Katus HA, et al. Cardiovascular ion channels as a molecular target of flavonoids. *Cardiovasc Ther* 2010; 28: e46-e52.
6. Mostofsky E, Johansen MB, Tjønneland A, et al. Chocolate intake and risk of clinically apparent atrial fibrillation: the Danish Diet, Cancer, and Health Study. *Heart* 2017; 103: 1163-1167.
7. Arts IC, van de Putte B and Hollman PC. Catechin contents of foods commonly consumed in The Netherlands. 1. Fruits, vegetables, staple foods, and processed foods. *J Agric Food Chem* 2000; 48: 1746-1751.
8. Tjønneland A, Olsen A, Boll K, et al. Study design, exposure variables, and socioeconomic determinants of participation in Diet, Cancer and Health: a population-based prospective cohort study of 57,053 men and women in Denmark. *Scand J Public Health* 2007; 35: 432-441.
9. Pedersen CB. The Danish civil registration system. *Scand J Public Health* 2011; 39: 22-25.
10. Petersson F, Baadsgaard M and Thygesen LC. Danish registers on personal labour market affiliation. *Scand J Public Health* 2011; 39: 95-98.
11. Lynge E, Sandegaard JL and Rebolj M. The Danish national patient register. *Scand J Public Health* 2011; 39: 30-33.
12. Overvad KIM, JøNneland AT, HaraldsdÓTtir J, et al. Development of a semiquantitative food frequency questionnaire to assess food, energy and nutrient intake in Denmark. *Int J Epidemiol* 1991; 20: 900-905.
13. Knaze V, Rothwell JA, Zamora-Ros R, et al. A new food-composition database for 437 polyphenols in 19,899 raw and prepared foods used to estimate polyphenol intakes in adults from 10 European countries. *Am J Clin Nutr* 2018; 108: 517-524.
14. Zamora-Ros R, Knaze V, Rothwell JA, et al. Dietary polyphenol intake in Europe: the European Prospective Investigation into Cancer and Nutrition (EPIC) study. *Eur J Nutr* 2016; 55: 1359-1375.
15. Rix TA, Riahi S, Overvad K, et al. Validity of the diagnoses atrial fibrillation and atrial flutter in a Danish patient registry. *Scand Cardiovasc J* 2012; 46: 149-153.
16. Schmidt M, Schmidt SAJ, Sandegaard JL, et al. The Danish National Patient Registry: a review of content, data quality, and research potential. *Clin Epidemiol* 2015; 7: 449.
17. Noordzij M, Leffondré K, van Stralen KJ, et al. When do we need competing risks methods for survival analysis in nephrology? *Nephrol Dial Transplant* 2013; 28: 2670-2677.
18. Hodgson JM and Croft KD. Tea flavonoids and cardiovascular health. *Mol Aspects Med* 2010; 31: 495-502.
19. Savelieva I, Kakouros N, Kourliouros A, et al. Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary prevention. *Europace* 2011; 13: 308-328.

340 20. Gronroos NN and Alonso A. Diet and risk of atrial fibrillation. *Circulation J* 2010;  
341 74: 2029-2038.

342 21. Rodrigo R, Korantzopoulos P, Cereceda M, et al. A randomized controlled trial to  
343 prevent post-operative atrial fibrillation by antioxidant reinforcement. *J Am Coll Cardiol*  
344 2013; 62: 1457-1465.

345 22. Bondonno NP, Lewis JR, Blekkenhorst LC, et al. Association of flavonoids and  
346 flavonoid-rich foods with all-cause mortality: The Blue Mountains Eye Study. *Clin Nutr*  
347 2019.

348 23. Fusi F, Spiga O, Trezza A, et al. The surge of flavonoids as novel, fine regulators of  
349 cardiovascular Cav channels. *Eur J Pharmacol* 2017; 796: 158-174.

350 24. Dalgaard F, Bondonno N, Murray K, et al. Higher Habitual Flavonoid Intake Is  
351 Associated with Lower Atherosclerotic Cardiovascular Disease Hospitalizations. *The*  
352 *Lancet Planetary Health* 2019. DOI: <http://dx.doi.org/10.2139/ssrn.3416721>

353 25. Croft KD. Dietary polyphenols: Antioxidants or not? *Arch Biochem Biophys* 2016;  
354 595: 120-124.

355 26. Liu Xm, Liu Yj, Huang Y, et al. Dietary total flavonoids intake and risk of mortality  
356 from all causes and cardiovascular disease in the general population: A systematic  
357 review and meta-analysis of cohort studies. *Mol Nutr Food Res* 2017; 61: 1601003.

358 27. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the  
359 management of patients with atrial fibrillation: a report of the American College of  
360 Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart  
361 Rhythm Society. *J Am Coll Cardiol* 2014; 64: e1-e76.

**Table 1. Baseline characteristics of study population**

	Total population n = 55 613	Total flavonoid intake quintiles				
		Q1 n = 11 123	Q2 n = 11 123	Q3 n = 11 122	Q4 n = 11 123	Q5 n = 11 122
Total flavonoid intake (g/d)	494 [287, 804]	173 [127, 213]	320 [287, 356]	494 [441, 548]	726 [659, 804]	1 201 [1 024, 1 435]
Sex (male)	26 344 (47.4)	6411 (57.6)	5669 (51.0)	5277 (47.4)	4935 (44.4)	4052 (36.4)
Age (years)	56 [52, 60]	56 [52, 60]	56 [52, 60]	56 [52, 60]	56 [52, 60]	55 [52, 60]
BMI (kg/m <sup>2</sup> )	25.5 [23.3, 28.2]	26.1 [23.7, 28.8]	25.9 [23.6, 28.5]	25.6 [23.3, 28.3]	25.3 [23.2, 27.9]	24.9 [22.7, 27.4]
MET score	66.6 (44.1)	61.5 (43.5)	66.0 (44.3)	67.4 (44.0)	68.8 (44.6)	69.4 (43.6)
Smoking status						
Never	19 532 (35.1)	2701 (24.3)	3720 (33.4)	3970 (35.7)	4429 (39.8)	4712 (42.4)
Former	15 985 (28.7)	2663 (23.9)	3008 (27.0)	3229 (29.0)	3562 (32.0)	3523 (31.7)
Current	20 096 (36.1)	5759 (51.8)	4394 (39.5)	3924 (35.3)	3131 (28.2)	2888 (26.0)
Education						
≤7 years	18 300 (32.9)	5091 (45.8)	4220 (37.9)	3578 (32.2)	3009 (27.1)	2402 (21.6)
8 – 10 years	25 640 (46.1)	4855 (43.6)	5229 (47.0)	5301 (47.7)	5273 (47.4)	4982 (44.8)
≥11 years	11 645 (20.9)	1171 (10.5)	1669 (15.0)	2240 (20.1)	2833 (25.5)	3732 (33.6)
Mean household income						
≤394 700 DKK/year	13 809 (24.8)	3324 (29.9)	2728 (24.5)	2700 (24.3)	2561 (23.0)	2496 (22.4)
394 701 – 570 930 DKK/year	13 906 (25.0)	3246 (29.2)	2979 (26.8)	2692 (24.2)	2579 (23.2)	2410 (21.7)
570 931 – 758 297 DKK/year	13 946 (25.1)	2889 (26.0)	3005 (27.0)	2878 (25.9)	2604 (23.4)	2570 (23.1)
> 758 297 DKK/year	13 952 (25.1)	1664 (15.0)	2410 (21.7)	2853 (25.6)	3378 (30.4)	3647 (32.8)
Hypertensive	8 997 (16.2)	1 781 (16.0)	1 839 (16.5)	1 834 (16.5)	1 798 (16.2)	1 755 (15.8)
Hypercholesterolemic	4 097 (7.4)	891 (8.0)	812 (7.3)	834 (7.5)	847 (7.6)	721 (6.5)
Comorbidities						
Diabetes	1 162 (2.1)	277 (2.5)	215 (1.9)	248 (2.2)	213 (1.9)	209 (1.9)
Heart failure	182 (0.3)	49 (0.4)	43 (0.4)	33 (0.3)	33 (0.3)	24 (0.2)

IHD	2 082 (3.7)	558 (5.0)	397 (3.6)	415 (3.7)	381 (3.4)	331 (3.0)
Stroke	702 (1.4)	192 (1.9)	141 (1.3)	128 (1.2)	120 (1.2)	121 (1.2)
COPD	838 (1.5)	219 ( 2.0)	184 ( 1.7)	155 ( 1.4)	148 ( 1.3)	132 ( 1.2)
CKD	200 (0.4)	43 ( 0.4)	30 ( 0.3)	44 ( 0.4)	42 ( 0.4)	41 ( 0.4)
Cancer	244 (0.4)	53 ( 0.5)	42 ( 0.4)	60 ( 0.5)	33 ( 0.3)	56 ( 0.5)
Hyperthyroidism	396 (0.7)	82 ( 0.7)	71 ( 0.6)	85 ( 0.8)	72 ( 0.6)	86 ( 0.8)

Medication use						
Insulin	378 (0.7)	78 ( 0.7)	63 ( 0.6)	86 ( 0.8)	80 ( 0.7)	71 ( 0.6)
Antihypertensive medication	6 770 (12.2)	1328 (11.9)	1404 (12.6)	1375 (12.4)	1342 (12.1)	1321 (11.9)
Statin	1 037 (1.9)	248 ( 2.2)	207 ( 1.9)	213 ( 1.9)	207 ( 1.9)	162 ( 1.5)
HRT						
Never	15 916 (28.6)	2594 (23.3)	3042 (27.4)	3256 (29.3)	3260 (29.3)	3764 (33.8)
Current	8 790 (15.8)	1289 (11.6)	1565 (14.1)	1692 (15.2)	1989 (17.9)	2255 (20.3)
Former	4 531 (8.1)	820 ( 7.4)	842 ( 7.6)	891 ( 8.0)	932 ( 8.4)	1046 ( 9.4)
NSAID	18 008 (32.6)	3510 (31.8)	3495 (31.6)	3613 (32.7)	3615 (32.7)	3775 (34.2)
Aspirin	7 015 (12.6)	1371 (12.3)	1351 (12.1)	1421 (12.8)	1381 (12.4)	1491 (13.4)

Dietary characteristics						
Energy (kj)	9 497 [7 855, 11 365]	8 610 [7 027, 10 387]	9 260 [7 713, 10 997]	9 748 [8 135, 11 583]	9 934 [8 321, 11 817]	9 922 [8 252, 11 881]
Total fish intake (g/d)	38 [25, 55]	33 [22, 49]	38 [25, 54]	40 [27, 57]	41 [28, 59]	40 [27, 57]
Red meat intake (g/d)	78 [56, 107]	80 [58, 108]	81 [59, 110]	80 [58, 110]	78 [57, 107]	72 [52, 99]
Processed meat intake (g/d)	25 [14, 40]	28 [17, 45]	26 [15, 42]	25 [14, 40]	23 [14, 38]	20 [11, 34]
Dietary fibre intake (g/d)	20 [16, 25]	16 [13, 20]	19 [16, 23]	21 [17, 25]	22 [18, 27]	23 [19, 29]
Saturated FA (g/d)	31 [24, 39]	29 [23, 37]	31 [24, 39]	32 [24, 40]	32 [25, 41]	32 [24, 41]
Polyunsaturated FA (g/d)	13 [10, 17]	12 [9, 16]	13 [10, 17]	14 [10, 18]	14 [11, 18]	14 [11, 18]
Monounsaturated FA (g/d)	27 [21, 35]	25 [21, 34]	28 [22, 35]	28 [22, 36]	28 [22, 36]	27 [21, 34]
Fruit intake (g/d)	171 [95, 281]	89 [44, 141]	161 [98, 237]	193 [114, 300]	224 [139, 360]	240 [141, 390]
Vegetable intake (g/d)	161 [105, 231]	114 [71, 170]	150 [99, 211]	168 [113, 235]	184 [127, 253]	196 [135, 272]
Alcohol intake (g/d)	13 [6, 31]	11 [3, 23]	13 [6, 24]	15 [6, 34]	14 [7, 32]	13 [6, 32]

---

Data expressed as median [IQR] or n (%), unless otherwise stated.

BMI, body mass index; CKD, chronic kidney disease; COPD, common obstructive pulmonary disease; DKK, Danish Krone; FA, fatty acids; HRT, hormone replacement therapy; IHD, ischemic heart disease; MET, metabolic equivalent; NSAID, Nonsteroidal anti-inflammatory drug.



**Table 2. Hazard ratios of incident atrial fibrillation by quintiles of flavonoid intake**

	Flavonoid intake quintiles				
	Q1	Q2	Q3	Q4	Q5
	(n=11 123)	(n=11 123)	(n=11 122)	(n=11 123)	(n=11 122)
<b>Total Flavonoids</b>					
No. events	1 398	1 301	1 265	1 179	1 143
Intake (mg/d)*	173 (6 – 251)	320 (251 – 394)	494 (394 – 601)	726 (601 – 908)	1201 (908 – 3552)
HR (95% CI)					
Model 1	ref.	<b>0.94 (0.90, 0.99)</b>	<b>0.91 (0.85, 0.96)</b>	<b>0.88 (0.83, 0.94)</b>	<b>0.87 (0.82, 0.93)</b>
Model 2	ref.	0.97 (0.92, 1.01)	0.95 (0.89, 1.00)	0.94 (0.89, 1.00)	0.95 (0.89, 1.02)
Model 4	ref.	0.97 (0.92, 1.01)	0.95 (0.89, 1.01)	0.95 (0.89, 1.01)	0.96 (0.90, 1.03)
<b>Flavonols</b>					
No. events	1 345	1 359	1 231	1 251	1 100
Intake (mg/d)*	15 (0 – 20)	26 (20 – 32)	38 (32 – 50)	66 (50 – 82)	116 (82 – 251)
HR (95% CI)					
Model 1	ref.	0.97 (0.93, 1.01)	<b>0.94 (0.89, 1.00)</b>	<b>0.89 (0.84, 0.95)</b>	0.88 (0.83, 0.94)
Model 2	ref.	0.97 (0.93, 1.01)	0.96 (0.90, 1.02)	0.95 (0.89, 1.01)	0.97 (0.91, 1.03)
Model 4	ref.	0.97 (0.93, 1.01)	0.95 (0.89, 1.01)	0.95 (0.89, 1.01)	0.96 (0.90, 1.03)
<b>Flavanol monomers</b>					
No. events	1 398	1 295	1 306	1 172	1 115
Intake (mg/d)*	14 (0 – 21)	30 (21 – 45)	66 (45 – 115)	260 (115 – 281)	473 (281 – 916)
HR (95% CI)					
Model 1	ref.	0.98 (0.96, 1.01)	<b>0.95 (0.89, 1.01)</b>	<b>0.88 (0.82, 0.93)</b>	<b>0.87 (0.82, 0.93)</b>
Model 2	ref.	0.98 (0.95, 1.01)	0.96 (0.90, 1.02)	0.96 (0.90, 1.02)	0.97 (0.91, 1.03)
Model 4	ref.	0.98 (0.96, 1.01)	0.96 (0.90, 1.02)	0.96 (0.90, 1.02)	0.97 (0.91, 1.04)
<b>Flavanol oligo+polymers</b>					

No. events	1 397	1 325	1 208	1 217	1 139
Intake (mg/d)*	91 (0 – 136)	179 (136 – 217)	255 (217 – 302)	359 (302 – 434)	536 (434 – 2254)
HR (95% CI)					
Model 1	ref.	<b>0.92 (0.88, 0.97)</b>	<b>0.89 (0.84, 0.94)</b>	<b>0.87 (0.82, 0.92)</b>	<b>0.86 (0.81, 0.92)</b>
Model 2	ref.	0.96 (0.92, 1.02)	0.94 (0.89, 1.00)	<b>0.92 (0.87, 0.98)</b>	0.93 (0.87, 1.00)
Model 4	ref.	0.96 (0.92, 1.02)	0.94 (0.89, 1.00)	<b>0.93 (0.87, 0.99)</b>	0.94 (0.88, 1.01)

### Anthocyanins

No. events	1 241	1 190	1 274	1 223	1 358
Intake (mg/d)*	5 (0 – 10)	13 (10 – 17)	20 (17 – 24)	36 (24 – 53)	71 (53 – 397)
HR (95% CI)					
Model 1	ref.	<b>0.93 (0.88, 0.98)</b>	<b>0.92 (0.86, 0.98)</b>	0.98 (0.92, 1.04)	1.06 (0.99, 1.13)
Model 2	ref.	0.99 (0.93, 1.04)	0.99 (0.92, 1.06)	1.01 (0.95, 1.08)	1.04 (0.97, 1.11)
Model 4	ref.	0.99 (0.94, 1.04)	0.99 (0.93, 1.06)	1.02 (0.95, 1.09)	1.04 (0.97, 1.12)

### Flavanones

No. events	1 301	1 294	1 231	1 212	1 248
Intake (mg/d)*	3 (0 – 6)	9 (6 – 13)	17 (13 – 26)	32 (26 – 49)	70 (49 – 564)
HR (95% CI)					
Model 1	ref.	0.97 (0.93, 1.02)	0.95 (0.88, 1.01)	<b>0.93 (0.87, 0.99)</b>	<b>0.95 (0.90, 1.02)</b>
Model 2	ref.	0.97 (0.93, 1.02)	0.95 (0.89, 1.02)	0.94 (0.88, 1.00)	0.96 (0.90, 1.02)
Model 4	ref.	0.98 (0.93, 1.02)	0.96 (0.89, 1.03)	0.94 (0.88, 1.00)	0.96 (0.90, 1.03)

### Flavones

No. events	1 327	1 249	1 259	1 186	1 265
Intake (mg/d)*	2 (0 – 3)	4 (3 – 4)	5 (4 – 6)	7 (6 – 9)	11 (9 – 51)
HR (95% CI)					
Model 1	ref.	<b>0.92 (0.86, 0.97)</b>	<b>0.89 (0.84, 0.95)</b>	<b>0.87 (0.82, 0.93)</b>	<b>0.89 (0.83, 0.95)</b>
Model 2	ref.	0.97 (0.91, 1.03)	0.95 (0.89, 1.01)	<b>0.93 (0.87, 0.99)</b>	<b>0.93 (0.87, 1.00)</b>

Model 4	ref.	0.97 (0.91, 1.03)	0.96 (0.89, 1.02)	0.94 (0.88, 1.00)	0.95 (0.88, 1.02)
---------	------	-------------------	-------------------	-------------------	-------------------

---

Hazard ratios (95% CI) for incident atrial fibrillation (first-time hospitalization or outpatient visit) during 23 years of follow-up, obtained from restricted cubic splines based on Cox proportional hazards models. Model 1 adjusted for age and sex; Model 2 adjusted for age, sex, BMI, smoking status, physical activity, alcohol intake, social economic status (income), and hyperthyroidism; Model 4 adjusted for all covariates in Model 2 plus intakes of fish, red meat, processed food, polyunsaturated fatty acids, monounsaturated fatty acids, and saturated fatty acids.

\*Median; range in parentheses (all such values). **Bold** indicates  $p < 0.05$ .


## FIGURE LEGENDS:

**Figure 1.** Associations between total flavonoid intake and incident atrial fibrillation (AF; first-time hospitalization or outpatient visit; n=7 291) and AF hospitalizations (n=6 286), in participants of the Danish Diet, Cancer and Health cohort. Hazard ratios for cubic splines are based on Cox proportional hazards models adjusted for age, sex, BMI, smoking status, physical activity, alcohol intake, social economic status (income), and hyperthyroidism and are comparing the specific level of total flavonoid intake (horizontal axis) to the median intake for participants in the lowest intake quintile (173 mg/d).


**Figure 2.** Hazard ratios based on cubic spline curves to describe the association between flavonoid subclass intakes (mg/day) and incident atrial fibrillation (first-time hospitalization or outpatient visit) among participants of the Danish Diet, Cancer and Health cohort. Hazard ratios are based on Cox proportional hazards models adjusted for age, sex, BMI, smoking status, physical activity, alcohol intake, social economic status (income), and hyperthyroidism and are comparing the specific level of flavonoid intake (horizontal axis) to the median intake for participants in the lowest intake quintile.

**Figure 3.** Multivariable-adjusted associations between total flavonoid intake and incident atrial fibrillation (first-time hospitalization or outpatient visit), stratified by baseline smoking status (smoker n=20 096; non-smoker n=35 517), alcohol intake (<20 g/day n=35 458; >20 g/day n=18 872), BMI (<30 kg/m<sup>2</sup> n=46 991; >30 kg/m<sup>2</sup> n=8 171), ischemic heart disease (IHD) status (IHD n=2 082; no IHD n=53 531), diabetes status (diabetic n=1 162; non-diabetic n=54 451), and hypertension status (hypertensive n=8 997; non-hypertensive n=46 616). Hazard ratios are based on Cox proportional hazards models and are comparing the specific level of total flavonoid intake


(horizontal axis) to the median intake for participants in the lowest intake quintile (173 mg/day). All analyses were adjusted for age, sex, BMI, smoking status, physical activity, alcohol intake, social economic status (income), and hyperthyroidism, not including the stratification variable for each subgroup if that variable was discrete.



**Figure 1.** Associations between total flavonoid intake and incident atrial fibrillation (AF; first-time hospitalization or outpatient visit;  $n=7\,291$ ) and AF hospitalizations ( $n=6\,286$ ), in participants of the Danish Diet, Cancer and Health cohort. Hazard ratios for cubic splines are based on Cox proportional hazards models adjusted for age, sex, BMI, smoking status, physical activity, alcohol intake, social economic status (income), and hyperthyroidism and are comparing the specific level of total flavonoid intake (horizontal axis) to the median intake for participants in the lowest intake quintile (173 mg/d).



**Figure 2.** Hazard ratios based on cubic spline curves to describe the association between flavonoid subclass intakes (mg/day) and incident atrial fibrillation (first-time hospitalization or outpatient visit) among participants of the Danish Diet, Cancer and Health cohort. Hazard ratios are based on Cox proportional hazards models adjusted for age, sex, BMI, smoking status, physical activity, alcohol intake, social economic status (income), and hyperthyroidism and are comparing the specific level of flavonoid intake (horizontal axis) to the median intake for participants in the lowest intake quintile.



**Figure 3.** Multivariable-adjusted associations between total flavonoid intake and incident atrial fibrillation (first-time hospitalization or outpatient visit), stratified by baseline smoking status (smoker n=20 096; non-smoker n=35 517), alcohol intake (<20 g/day n=35 458; >20 g/day n=18 872), BMI (<30 kg/m<sup>2</sup> n=46 991; >30 kg/m<sup>2</sup> n=8 171), ischemic heart disease (IHD) status (IHD n=2 082; no IHD n=53 531), diabetes status (diabetic n=1 162; non-diabetic n=54 451), and



hypertension status (hypertensive n=8 997; non-hypertensive n=46 616). Hazard ratios are based on Cox proportional hazards models and are comparing the specific level of total flavonoid intake (horizontal axis) to the median intake for participants in the lowest intake quintile (173 mg/day). All analyses were adjusted for age, sex, BMI, smoking status, physical activity, alcohol intake, social economic status (income), and hyperthyroidism, not including the stratification variable for each subgroup if that variable was discrete.